Early viral kinetics and treatment outcome in combination of high‐dose interferon induction vs. pegylated interferon plus ribavirin for naïve patients infected with hepatitis C virus of genotype 1b and high viral load

Keywords

Developing country, Principal (computer security), World War II, Political science, Development economics

References

• The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagenShane Crotty, David Maag, Jamie J. Arnold — 2000
• Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection.Akihito Tsubota, Yuichi Hirose, Namiki Izumi — 2003
• Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.Adrian M. Di Bisceglie, Hari S. Conjeevaram, Michael Fried — 1995
• Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.Matthew Cramp, S. Rossol, Shilpa Chokshi — 2000
• Standardization of Hepatitis C Virus RNA QuantificationJean–Michel Pawlotsky, Magali Bouvier‐Alias, Christophe Hézode — 2000
• Impact of interferon alfa‐2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis CThierry Poynard, John G. McHutchison, Gary L. Davis — 2000
• Monitoring of viral levels during therapy of hepatitis CGary L. Davis — 2002
• Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamideRobert W. Sidwell, John H. Huffman, Lois G. P. Khare — 1972
• Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.Stefan Zeuzem, Jung‐Hun Lee, Eva Herrmann — 2001
• Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.Johnson Y.N. Lau, Gary L. Davis, Jared C. Kniffen — 1993
• Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long‐term observation study of 1,643 patients using statistical bias correction with proportional hazard analysisKenji Ikeda, Satoshi Saitoh, Yasuji Arase — 1999
• Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region.Naoya Enomoto, Ikuo Sakuma, Yasuhiro Asahina — 1995
• Molecular mechanisms of action of ribavirin.Jean L. Patterson, Roberto Fernandez-Larsson — 1990
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.Avidan U. Neumann, Nancy P. Lam, Harel Dahari — 1998
• Quantification of the initial decline of serum hepatitis c virus RNA and response to interferon alfaStefan Zeuzem, Jung-Hun Lee, Alexa Franke — 1998
• Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferonEva Herrmann, Jung‐Hun Lee, George Marinos — 2003
• Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical modelFrank C. Bekkering, Carlos Stalgis, John G. McHutchison — 2001
• Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa‐2b plus ribavirinMarı́a Buti, J.F. Sánchez-Ávila, Yoav Lurie — 2002
• Viral Kinetics and Treatment Response in Patients with Hepatitis C During Induction and Standard Interferon Therapy in Combination with RibavirinThomas Carlsson, Ola Weiland, Olle Reichard — 2002
• Factors predictive of response to interferon‐α therapy in hepatitis C virus infectionAkihito Tsubota, Kazuaki Chayama, Kenji Ikeda — 1994

Cited by

• Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage.MF Derbala — 2006
• Genotype 1b・高ウイルス量のC型慢性肝炎に対する response-guided therapy の検討紀朋 島田, 海 吉澤, 麻紀子 井家 — 2009
• Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.Goran Hauser, Tahany Awad, Jesper Brok — 2014
• Establishment of a Practical Workflow Using a Next Generation Sequencer to Search for Novel SNPs Associated with the Anti-HCV Treatment ResponseTsutomu Takeda, Masaya Sugiyama, Tatsuya Kanto — 2014
• Sustained virological responses following standard anti‐viral therapy in decompensated HCV‐infected cirrhotic patientsA. Iacobellis, Massimo Siciliano, B.E. Annicchiarico — 2009
• Hepatitis C virus: genotype identification and interactions between viral proteasesEva Žusinaite — 2005
• Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trialsRoger Chou, Susan Carson, B. K. S. Chan — 2008
• Prospective study on early virologic response to treatment with interferon alpha-2b plus ribavirin in patients with chronic hepatitis C genotype 1b.Masahito Nagaki, Motoaki Imose, Taku Naiki — 2005
• IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infectionMartin Lagging, Ana I. Romero, Johan Westin — 2006
• Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin TreatmentNorio Akuta, Fumitaka Suzuki, Miharu Hirakawa — 2012
• Evaluation of long‐term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral loadHitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura — 2007
• Identifying HCV genotype 1 patients at risk of relapseMarc Deschênes, Vincent G. Bain, Samuel S. Lee — 2010
• Pegylated Interferon Alpha‐2b for Patients with HCV Recurrence and Graft Fibrosis Following Liver TransplantationMathis Heydtmann, D. Freshwater, Tracey Dudley — 2006
• Amino Acid Substitutions in the Hepatitis C Virus Core Region and Lipid Metabolism Are Associated with Hepatocarcinogenesis in Nonresponders to Interferon plus Ribavirin Combination TherapyYuya Seko, Norio Akuta, Fumitaka Suzuki — 2012
• Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4Hamad Al Ashgar, Ahmed Helmy, Mohamed Q. Khan — 2009
• [Treatment options for chronic hepatitis C virus infection].I Bojić, Ljubisa Dokic, Svetlana Minić — 2006
• Triple therapy of initial high‐dose interferon with ribavirin and amantadine for patients with chronic hepatitis CHirokazu Uyama, Hideji Nakamura, Eijiro Hayashi — 2007
• Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.Ana I. Romero, Martin Lagging, Johan Westin — 2006
• Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of ViremiaNorio Akuta, Fumitaka Suzuki, Yusuke Kawamura — 2007
• Sustained Virologic Response to Peginterferon α-2a and Ribavirin in 335 Patients with Chronic Hepatitis C: A Tertiary Care Center ExperienceHamad Al Ashgar, MohammedQ Khan, Ahmed Helmy — 2008

Related papers

• An evolutionary theory of economic changeBrian J. Loasby, Richard R. Nelson, Sidney G. Winter — 1983
• Managing technological development : lessons from the newly industrializing countriesCarl J. Dahlman, Bruce Ross-Larson, Larry E. Westphal — 1987
• Technological innovation and industrial research in JapanKeichi Oshima — 1984
• Issues in the technological development of China's electronic sectorAnupan Khanna — 1986
• Inside the Black Box: Technology and EconomicsUlrich Kohli, Nathan Rosenberg — 1984
• The World Technological Revolution and China's Policy of Technological InnovationYuansheng Ye — 1987
• A Paradigm Shift in Russia’s Industrial Policy: from a Raw Model to Innovative Technological Growth PointsTatiana V. Skryl — 2017
• A description of some factors affecting technological innovation in industry in the United Kingdom and some remedies to improve the climateKeith White-Hunt, Andrzej Pomykalski — 1985
• Technology transfer in China's industrial development : a study concentrating on the electronics sector and the television industry.Zhicun Gao — 2003